title: [Consensus paper treatment of acute traveler's diarrhea. Practice recommendation for travel advice].
abstract: In times of mass tourism, traveler's diarrhea is one of the most common health problems of long-distance travel. Globally, some 40 million cases occur annually. Travellers to risk areas should therefore be comprehensively advised beforehand, as to what action to take in case of an acute traveler's diarrhea and what drugs to add to their first-aid kit. To date none, or hardly any specific studies or valid specific guidelines for the treatment of traveler's diarrhea are available for Germany.
  
  
  
  Drafting a consensus paper based on results of a specialists' meeting to evaluate therapeutic options in the treatment of acute uncomplicated travelers' diarrhea. The foundation for the present consensus recommendations is current evidence on antidiarrheals available in Germany for symptomatic treatment of gastrointestinal infections, summarized in the S2k guideline for gastrointestinal infections and Whipple's disease. Further taken into account for the present consensus recommendations were Pubmed-listed publications on symptomatic treatment of traveler's diarrhea, practical aspects, and the experts' experience in travel medicine.
  
  
  
  For the treatment of acute uncomplicated traveler's diarrhea - more than 90 % of all cases - the secretion inhibitor racecadotril is considered first choice, based on our evaluation criteria. The previously usual practice of recommending the antimotility drug loperamide as first choice should be reconsidered, in favor of the recent active ingredient racecadotril. Antibiotics should be used only in complicated cases. A large number of travelers who generally demand antibiotic therapy should be disabused of their expectations. Other therapeutic measures that are currently available for the treatment of acute diarrhea while traveling play a subordinate role.
authors.affiliation: BCRT - Berliner Centrum für Reise- und Tropenmedizin, Friedrichstr. 134, D-10117, Berlin, Deutschland. jelinek@bcrt.de.|Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Klinikum der Universität zu Köln, Köln, Deutschland. jelinek@bcrt.de.
authors.forename: Tomas
authors.initials: T
authors.lastname: Jelinek
authors.affiliation: Abteilung für Infektions- und Tropenmedizin, Klinikum der Universität München, München, Deutschland.
authors.forename: Hans-Dieter
authors.initials: HD
authors.lastname: Nothdurft
authors.affiliation: Labor Hannover MVZ GmbH, Hannover, Deutschland.
authors.forename: Martin
authors.initials: M
authors.lastname: Haditsch
authors.affiliation: Klinikum Ernst von Bergmann, Potsdam, Deutschland.
authors.forename: Thomas
authors.initials: T
authors.lastname: Weinke
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000930:Antidiarrheals / Q000627:therapeutic use; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D004403:Dysentery / Q000188:drug therapy* / Q000209:etiology; D005858:Germany; D006801:Humans; D017410:Practice Guidelines as Topic; D015244:Thiorphan / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014195:Travel
chemical_list: D000900:Anti-Bacterial Agents; D000930:Antidiarrheals; C049331:racecadotril; D015244:Thiorphan
keywords: consensus recommendation; loperamide; racecadotril; traveler’s diarrhea